readthroughSign in
Aug 21, 2026Weekly roundup

GSK posts propellant trial results; recruits for three Phase 3 felcorekibart studies

GSK reported results from a completed inhaler propellant study and continues enrollment in three Phase 3 trials of felcorekibart in COPD and asthma.

This week's GSK activity centered on a completed early-phase inhaler study with new results and ongoing recruitment across three Phase 3 felcorekibart trials, plus a collaborator-sponsored cancer registry.

  • Results were posted for a completed Phase 1 crossover study comparing two inhaler propellants, HFA-152a and HFA-134a, in adults with mild asthma. The purpose of the study is to assess the propellants,1 - Difluoroethane [HFA-152a] (Test) and 1,1,1,2-Tetrafluoroethane [HFA-134a] (Reference) for their potential to cause the airways to tighten when delivered through pressurized metered dose inhalers (pMDI).1 The trial enrolled 20 participants (actual)1 and its primary completion was 2025-06-04 (actual)1, with results first posted August 21, 2026.
  • "PERSIST COPD-1" (NCT07780669), a Phase 3 trial of GSK5784283 (felcorekibart) in moderate to very severe COPD, is recruiting at two U.S. sites. The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.2 Enrollment: 624 participants (estimated)2.
  • "PERSIST COPD-2" (NCT07780656), a companion Phase 3 study with the same design and endpoint, is recruiting at one of its four listed U.S. sites. 4 sites in 1 country: United States - GSK Investigational Site, Miami, Florida, United States (not yet recruiting) - GSK Investigational Site, Tampa, Florida, United States (recruiting) - GSK Investigational Site, Rapid City, South Dakota, United States (not yet recruiting) - GSK Investigational Site, West Point, Utah, United States (not yet recruiting)3.
  • "PERSIST ASTHMA-1" (NCT07780643), a Phase 3 trial of felcorekibart as add-on therapy in uncontrolled asthma, is recruiting at one U.S. site. The study aims to demonstrate the superiority of GSK5784283 compared to placebo in reducing the annualized rate of clinically meaningful asthma exacerbations.4 Enrollment: 514 participants (estimated)4, ages 12 to 80.
  • GSK is a collaborator, not the lead sponsor, on the ABCSG R07 Rectal Cancer Registry, an observational study led by the Austrian Breast & Colorectal Cancer Study Group that is not yet recruiting. The ABCSG R07 Rectal Cancer Registry (RCR) study will provide real-world data that reflect the current therapeutic landscape for participants.5

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.